

## N. Ireland Cancer Registry Implications of Research for Services

NICR Lead Author <i>(Office use only)</i>
Paper ID <i>(Office use only)</i>
Date Submitted to NICR Steering Group <a href="#">Click here to enter a date.</a> <i>(Office use only)</i>

<b>Paper Title</b>	Complete cancer prevalence in Europe in 2020 by disease duration
<b>Authors</b>	DeAngelis, R., Demuru, E., Baili, P.,...EUROCARE-6 Working Group, et al
<b>Journal</b>	Lancet Oncology
<b>DOI</b>	<a href="https://doi.org/10.1016/S1470-2045(23)00646-0">https://doi.org/10.1016/S1470-2045(23)00646-0</a>
<b>Funders</b>	Northern Ireland Cancer Registry is funded by the Public Health Agency of Northern Ireland.
<b>Full paper available online</b>	YES <input checked="" type="checkbox"/> NO <input type="checkbox"/> NOT YET <input type="checkbox"/>
<b>Conclusion</b>	<p>Complete information on cancer prevalence across European countries was produced using population-based cancer registry data from the EUROCARE-6 study from 61 cancer registries across 29 European countries.</p> <p>In 2020, 23.7 million people (5% of the population) were estimated to be alive after a cancer diagnosis in Europe. The 5 leading tumours in females were breast, colorectal cancer, uterine, melanoma and thyroid cancers and for males were prostate, colorectal, bladder, melanoma and kidney cancers.</p>
<b>What this means for the service</b>	<p>These findings provide country level European data to support evidence-based policies to improve the quality of life, care, and rehabilitation of patients with cancer throughout the disease pathway.</p> <p>Population-based cancer registries should be used to do further European-level analysis, including estimation of time to cure by stage at diagnosis in prevalent cases.</p>